Reading TEM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TEM free→Reading TEM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TEM free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, but risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, TEM is above typical for the sector. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $50.56. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.61x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.15 → $-0.15 (-3.4% / 30d). 5 raised, 7 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 59% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$280.
How much price usually moves either way.
On a bad day, this stock has moved -$599.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,896.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If sector revenue growth picks up, it could benefit TEMPUS AI's performance.
Confirms one read:Health Care sector revenue growth is speeding up toward 10% or more.
Confirms the other:Sector revenue growth keeps slowing down below 10%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Increase 2026 revenue guidance to $1.59B-$1.60B
FDA clearance enhances growth potential and revenue outlook.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Agreement. Indenture and Notes On May 12, 2026, Tempus AI, Inc. (the “ Company ”) completed its previously announced private offering (the “ Offering ”) of $460.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “ Notes ”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $60.0 million principal amount of the Notes. The Notes were issued pursuant to an indenture, dated May 12, 2026 (the “ I…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
TXG 10X Genomics, Inc. | Typical Show detailsSector percentile: 47 of 100 | expensive | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 79 of 100 | full | high |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Tempus aims for a 25% annual growth by increasing its 2026 revenue guidance to $1.59 billion to $1.60 billion.
Tempus aims to achieve an Adjusted EBITDA of approximately $65 million for the fiscal year 2026.
Tempus completed a $460 million offering of Convertible Senior Notes due 2032.
Strategic partnership could drive revenue growth and market position.
of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific refere…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Termination of a Material Definitive Agreement. On May 12, 2026, the Company used a portion of the net proceeds from the Offering to repay in full all obligations outstanding under that certain Credit Agreement, dated as of September 22, 2022, among the Company, Ares Capital Corporation, as administrative agent for the lenders, ACF Finco I LP, as revolving agent for the lenders and the lenders party thereto (as amended, the “Credit Agreement”). In connection with this repayment, the Credit Ag…
Unregistered Sale of Equity Securities. The information set forth under